2023
IL-7R licenses a population of epigenetically poised memory CD8+ T cells with superior antitumor efficacy that are critical for melanoma memory
Micevic G, Daniels A, Flem-Karlsen K, Park K, Talty R, McGeary M, Mirza H, Blackburn H, Sefik E, Cheung J, Hornick N, Aizenbud L, Joshi N, Kluger H, Iwasaki A, Bosenberg M, Flavell R. IL-7R licenses a population of epigenetically poised memory CD8+ T cells with superior antitumor efficacy that are critical for melanoma memory. Proceedings Of The National Academy Of Sciences Of The United States Of America 2023, 120: e2304319120. PMID: 37459511, PMCID: PMC10372654, DOI: 10.1073/pnas.2304319120.Peer-Reviewed Original ResearchConceptsIL-7R expressionT cellsIL-7RAntitumor memorySuperior antitumor efficacyCell-based therapiesTumor-specific T cellsAntigen-specific T cellsAntitumor efficacyPowerful antitumor immune responseMarkers of exhaustionTumor-specific CD8Antitumor immune responseIndependent prognostic factorAntitumor immune memoryMemory T cellsMajor risk factorSuperior antitumor activityFunctional CD8Memory CD8Prognostic factorsSurgical resectionAdvanced melanomaLymph nodesNaive mice
2021
Metabolism of Innate Immune Cells in Cancer
Talty R, Olino K. Metabolism of Innate Immune Cells in Cancer. Cancers 2021, 13: 904. PMID: 33670082, PMCID: PMC7927092, DOI: 10.3390/cancers13040904.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsInnate immune cellsImmune cellsAntitumor immune responseImmune checkpoint blockadeAdoptive cell transferOngoing clinical applicationsSpecific metabolic requirementsInnate immune systemCheckpoint blockadeTumor clearanceAntitumor responseImmune activationMetabolic requirementsT cellsImmune responseEffector functionsImmune systemCell transferTumor microenvironmentCancer cellsPrimary effectorClinical applicationCancerCellsMetabolism